NAPRT Silencing in FH-Deficient Renal Cell Carcinoma Confers Therapeutic Vulnerabilities via NAD+ Depletion.
Noronha KJ, Lucas KN, Paradkar S, Edmonds J, Friedman S, Murray MA, Liu S, Sajed DP, Sachs C, Spurrier J, Raponi M, Liang J, Zeng H, Sundaram RK, Shuch B, Vasquez JC, Bindra RS.
Noronha KJ, et al.
Mol Cancer Res. 2024 Oct 2;22(10):973-988. doi: 10.1158/1541-7786.MCR-23-1003.
Mol Cancer Res. 2024.
PMID: 38949523
Free PMC article.